Antonio De Vincentis

Can we predict failure to #OCA in #PBC patients? The simple answer is YES❗️ OCA-response score: a novel tool to drive treatment allocation for 2nd-line therapies @AASLDtweets @EASLedu #livertwitter Read full paper on the two largest OCA cohorts cghjournal.org/article/S1542-…

Acute‑on‑chronic liver failure 🏥 clinical characteristics 🩺 pathophysiology 🫘🩸 🧠 🫁 management of individual organ dysfunction: liver, coagulation, kidney, brain, lung 🫀 circulation 🏥 #ICU management 🟫 liver transplantation Free to read @yourICM 🔓rdcu.be/diYyq

Another great contribution shared at #easlcongress! Willem Pieter Brouwer presented: "METABOLIC DYSFUNCTION ASSOCIATED FIBROSIS-5 (MAF-5) SCORE ACCURATELY IDENTIFIES AT-RISK LIVER FIBROSIS AND PREDICTS PROGNOSIS IN A POPULATION-BASED SETTING" Aims of this study: "To design a non-invasive test to predict (metabolic dysfunction associated) significant fibrosis in a population-based setting". Conclusions: • "The MAF-5 is a validated, age-independent, inexpensive referral tool to identify patients at high risk of liver fibrosis in the primary care setting • It outperformed other NITs in the primary care setting especially in the younger and older populations and had a stable performance across (heterogeneous) populations • It was significantly associated with biopsy-proven fibrosis severity in NAFLD/NASH patients • MAF-5 was significantly associated with all-cause mortality • The MAF-5 score may therefore be a good alternative" Laurens van Kleef, @FrancqueSven, Harry Janssen, Willem Pieter Brouwer et al.